Blog

Matthew Kurian: From ASCENT-04 may reshape frontline therapy for mTNBC

Matthew Kurian/youtube.com

Apr 23, 2025, 10:12

Matthew Kurian: From ASCENT-04 may reshape frontline therapy for mTNBC

Matthew Kurian, Assistant professor of medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:

“Practice-Changing Data in Metastatic TNBC?

The press release from ASCENT-04 is in—and it may reshape frontline therapy for metastatic triple-negative breast cancer (mTNBC)!

Gilead’s sacituzumab govitecan (Trodelvy) + pembrolizumab (Keytruda) significantly improved progression-free survival vs chemo + pembrolizumab in PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (mTNBC).

This is the first-ever antibody-drug conjugate (ADC) + immunotherapy (IO) combo to outperform chemo + IO in metastatic breast cancer.

Why it matters:

KEYNOTE-355 established chemo + pembrolizumab in CPS ≥10 as the standard.
Now, ASCENT-04 shows Trodelvy + Keytruda may be more effective in the same population.
This could signal a paradigm shift: ADCs as frontline IO partners, not just later-line salvage agents.

The future of TNBC treatment may no longer rely on conventional chemo—this is a huge moment!

Looking forward to full results at ASCO25.”

ADC antibody-drug conjugate ASCENT-04 ASCO25 cancer fight against cancer Global fight against cancer immunotherapy KEYNOTE-355 Matthew Kurian metastatic TNBC mTNBC OncoDaily Oncology pembrolizumab Sacituzumab govitecan Trodelvy University of Kentucky College of Medicine

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book